Vascular Biogenics reported 9.68M in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Bluebird Bio BLUE:US $ 108.92M 13.37M
Capricor Therapeutics CAPR:US $ 7.32M 509.78K
Eleven Biotherapeutics EBIO:US 835K 10.21M
Epizyme EPZM:US $ 57.33M 2.29M
Infinity Pharmaceuticals INFI:US $ 12.7M 355K
Newlink Genetics NLNK:US 8.33M 485K
Prothena PRTA:US 44.52M 5.42M
Vascular Biogenics VBLT:US 9.68M 999K